Other Agreements - Additional Information (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock				5,587
Asset purchase agreement fixed payments paid for first two years	$ 740,000			$ 740,000
Percentage on annual revenues for cash consideration to be paid				6.00%
Asset purchase agreement aggregate cash compensation paid	$ 15,000,000			$ 15,000,000
Deferred payment obligation interest percentage	5.00%			5.00%
Discount rate used to calculate asset purchase obligation				2.50%
Research and development	$ 2,611,591		$ 953,222	$ 4,605,692	$ 1,641,437
Agreement expiration date				Oct. 31, 2019
Description on termination of agreement				The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy
Revenues	1,895,816		790,551	$ 2,761,048	1,814,866
Recognition of deferred revenue				87,952
Collaborative Arrangement
Other Agreements [Line Items]
Revenues	29,562			$ 29,562
LTC
Other Agreements [Line Items]
Agreement commencement period				2016-03
Non-cancellable purchase order value						$ 250,000
Agreement expiration date				2021-03
Automatic renewal term of agreement				2 years
Agreement termination notice period				60 days
Number of days material breach remains uncured				30 days
Bristol-Myers Squibb
Other Agreements [Line Items]
Agreement expiration date				May 11, 2019
Agreement termination notice period				90 days
Number of days material breach remains uncured				60 days
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	1,000,000			$ 1,000,000
Research and development		$ 100,000
Invetech PTY Ltd. Agreement
Other Agreements [Line Items]
Research and development	1,168,858		0	1,873,158	0
Growth Term Loan A
Other Agreements [Line Items]
Debt instrument, amortization expense	50,224		52,512	102,132	89,032
Minimum payments of pledged intangible assets due in 2014	868,750			868,750
Minimum payments of pledged intangible assets due in 2015	868,750			868,750
Minimum payments of pledged intangible assets due in first quarter of 2016	868,750			868,750
Minimum payments of pledged intangible assets due in second quarter of 2016	181,250			181,250
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due in current year	543,750			543,750
Asset purchase agreement quarterly installments due in 2017	800,000			800,000
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	179,154	$ 283,621		179,154
Debt instrument, amortization expense	52,385		$ 51,180	104,467	$ 177,751
Minimum | NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018	$ 400,000			$ 400,000